Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders

An isolated antibody that binds human homodimeric IL-17A and human heterodimeric IL-17AF or antigen-binding portion thereof, comprising a heavy chain variable region (VH) and a light chain variable region NO:

• a. wherein said VH comprises, in sequence, the three Complementarity Determining Regions (CDRs) set forth as amino acid sequences SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:3 and wherein said comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:42, SEQ ID NO:23, SEQ ID NO:11;
• or
• b. wherein said VH comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and wherein said VL comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:41, SEQ ID NO:5, SEQ ID NO:6.

An isolated antibody that binds human homodimeric IL-17A and human heterodimeric IL-17AF or antigen-binding portion thereof, comprising a VH and a VL, wherein said VH comprises the three CDRs of the amino acid sequence set forth as SEQ ID NO:12 and wherein said VL comprise the three CDRs of the amino acid sequence set forth as SEQ ID NO:43.

An isolated antibody that binds human homodimeric IL-17A and human heterodimeric IL-17AF, comprising a heavy chain and a light chain, wherein said heavy chain comprises the three CDRs of the amino acid sequence set forth as SEQ ID NO:12 and wherein said light chain comprise the three CDRs of the amino acid sequence set forth as SEQ ID NO:43.

The isolated antibody according to claim 50, which has a K for human IL-17A below 100 pM as measured by Biacore™.

A pharmaceutical composition comprising the isolated antibody or antigen-binding portion thereof according to any one of the above claims in combination with one or more pharmaceutically acceptable excipient, diluent or carrier.